1383814-64-9 Usage
Description
(1R,2S,5R)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide is a complex organic compound with a unique molecular structure. It is characterized by its bicyclic ring system and the presence of a hydroxyl and carboxamide functional groups. (1R,2S,5R)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide is known for its role as an impurity in the pharmaceutical compound Avibactam, which is a novel β-lactamase inhibitor.
Uses
Used in Pharmaceutical Industry:
(1R,2S,5R)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide is used as an impurity in the production of Avibactam, a novel β-lactamase inhibitor. Its presence in the synthesis process of Avibactam is significant as it can impact the overall efficacy and safety of the final product. The compound is crucial in the development and optimization of Avibactam's production methods to ensure its purity and effectiveness as a potent inhibitor of lactamase from Mycobacterium tuberculosis.
In the context of Avibactam's application, (1R,2S,5R)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide serves as a critical reference point for researchers and pharmaceutical companies to understand the synthesis process, optimize the production, and minimize the presence of impurities. This, in turn, helps to improve the overall quality and effectiveness of Avibactam as a β-lactamase inhibitor, ultimately contributing to the development of more effective treatments for tuberculosis and other bacterial infections.
Check Digit Verification of cas no
The CAS Registry Mumber 1383814-64-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,8,3,8,1 and 4 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1383814-64:
(9*1)+(8*3)+(7*8)+(6*3)+(5*8)+(4*1)+(3*4)+(2*6)+(1*4)=179
179 % 10 = 9
So 1383814-64-9 is a valid CAS Registry Number.
1383814-64-9Relevant articles and documents
2-CYANOPYRROLDINES, -PIPERIDINES OR -DAZEPINES AS HYPERGLYCEMIC AGENTS
-
Page/Page column 50-51, (2021/08/27)
Nitrogen containing compounds of Formula (I), pharmaceutical compositions comprising these compounds and their use in treating hypoglycaemia is disclosed.
Avibactam intermediate, and preparation method and application of avibactam intermediate
-
Paragraph 0037; 0045-0046; 0048-0049; 0051-0052; 0053-0058, (2019/09/17)
The invention discloses an avibactam intermediate, and a preparation method of the avibactam intermediate. The preparation method comprises the steps of allowing a compound II to react with a sulfonation reagent in the presence of an alkaline agent and then react with the alkaline agent to form the avibactam intermediate, wherein the alkaline agent is trialkylamine, pyridine, alkylpyridine, N-alkylpiperidine, dialkyl phenylamine or dialkyl benzylamine; alkyl in trialkyl amine is C5-8 alkyl; alkyl in alkyl pyridine in C1-4 alkyl; alkyl in N-alkylpiperidine is C1-4 alkyl; alkyl in dialkyl phenylamine is C1-4 alkyl; and alkyl in dialkyl benzylamine is C1-4 alkyl. Compared with the traditional method, the method adopts the alkaline agent with appropriate alkalinity to substitute the traditional alkaline agent; the alkaline agent can react with the compound II in a step directly with the sulfonation reagent; the post-treatment is simple; and the method is more suitable for industrial mass production.
Beta-lactamase inhibitors and uses thereof
-
Page/Page column 82; 83, (2018/10/24)
β-Lactamase inhibiting compounds, therapeutic methods of using the β-lactamase inhibiting compounds, particularly in combination with β-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The β-lactamase inhibiting compounds are suitable for oral administration.
